Sellas Life Sciences Group has reported positive topline results from a pivotal Phase III clinical trial evaluating its investigational cancer vaccine galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML). The company announced on November 17, 2026, that the global REGAL study met its primary endpoint of overall survival, reporting a median overall survival of 24.0 months among patients assigned to GPS maintenance therapy compared with 14.7 months among those receiving best available treatment.

The reported result represents a potentially important development for a particularly vulnerable group of AML patients: people whose disease has returned, who have achieved another remission following salvage treatment, but who cannot undergo an allogeneic stem-cell transplant. For this population, maintaining remission and extending survival remain difficult clinical challenges.

Sellas reported a hazard ratio of 0.59 and a two-sided p-value of 0.035. The hazard ratio corresponds to a 41% relative reduction in the hazard of death in the GPS group compared with the control group during the analysed period. The result met the trial's prespecified statistical threshold for its primary endpoint.

The announcement is significant for the company and for the development of WT1-targeted immunotherapy. However, the findings remain topline company-reported results. The detailed secondary-endpoint analysis, additional prespecified evaluations and full clinical dataset have not yet been presented in a peer-reviewed publication. GPS remains investigational, and the U.S. Food and Drug Administration (FDA) has not approved it for commercial use.

  1. What Sellas announced on November 17

Sellas announced that its Phase III REGAL trial achieved a statistically significant improvement in overall survival, comparing GPS maintenance monotherapy with investigator-selected best available treatment.

The company reported the following principal results:

  • Median overall survival in the GPS group: 24.0 months.
  • Median overall survival in the best available treatment group: 14.7 months.
  • Hazard ratio for death: 0.59.
  • Relative reduction in the hazard of death: 41%.
  • Two-sided p-value: 0.035.
  • Total randomised participants: 126.
  • Trial allocation: 1:1.
  • Primary endpoint: overall survival.

The median survival difference between the two groups was 9.3 months. This is the difference between the reported group medians; it should not be interpreted as a guaranteed additional 9.3 months of life for every patient receiving GPS.

The trial's primary endpoint was overall survival, an important measure in cancer research because it evaluates how long participants remain alive following the defined starting point. Unlike some intermediate measures, overall survival directly records death from any cause.

The announcement follows the company's October 28 disclosure that the trial had reached its prespecified 80th death event. That event triggered the final analysis under the study's statistical plan. Sellas subsequently completed the analysis and announced its topline result on November 17.

  1. Why the REGAL result matters for acute myeloid leukemia

Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow. It develops when abnormal immature blood-forming cells multiply and interfere with the production of normal blood cells.

AML can progress rapidly and may cause symptoms associated with anaemia, infections and bleeding. Treatment generally depends on factors such as the patient's age, general health, disease characteristics, genetic and molecular findings, previous treatment history and ability to tolerate intensive therapy.

Some patients achieve remission after initial treatment. However, remission does not always mean that every malignant cell has been eliminated. Residual leukemia cells can remain and contribute to relapse.

When AML returns, patients may receive salvage therapy intended to bring the disease back under control. Some achieve a second complete remission or a later remission. For eligible patients, an allogeneic stem-cell transplant may be considered as a potentially curative treatment strategy.

But transplantation is not feasible for everyone. Medical fitness, donor availability, disease status, age, organ function and other clinical factors can limit eligibility. Patients who cannot undergo transplantation may face a difficult period in which the risk of another relapse remains substantial.

REGAL was designed to investigate whether GPS could serve as a maintenance treatment in this setting. Its findings therefore relate to a defined high-risk population rather than the entire AML patient community.

  1. The patients enrolled in the REGAL trial

The REGAL study evaluated adults with AML who had achieved a second or later complete remission, known as CR2 or later, or complete remission with insufficient platelet recovery, known as CRp2 or later.

Participants had reached that remission following second- or later-line salvage therapy. They were also ineligible for, or unable to undergo, allogeneic stem-cell transplantation.

This distinction is essential when interpreting the results. The study did not test GPS as a general first-line AML treatment, nor did it establish its effectiveness for every patient who achieves an initial remission.

The trial's focus was maintenance therapy after a later remission. Maintenance treatment is intended to help preserve a response achieved through earlier therapy and delay disease recurrence.

Sellas reported that 126 participants were randomised in a 1:1 allocation. One group received GPS monotherapy, while the other received investigator-selected best available treatment.

The control options included observation, hypomethylating agents, venetoclax and/or low-dose cytarabine. The investigator's choice was therefore not one identical drug regimen administered to every control participant. It reflected the treatment options selected within the study framework.

The open-label design meant that the treatment assignment was known to participants and investigators. The primary endpoint, however, was overall survival, an objective outcome based on death events rather than a subjective assessment of tumour response.

  1. Understanding the 24.0-month median overall survival

Median overall survival is the time point at which half the participants in a group have died and half remain alive, according to the statistical analysis.

In REGAL, Sellas reported a median overall survival of 24.0 months in the GPS group and 14.7 months in the best available treatment group.

The difference of 9.3 months is an important headline result. It suggests that the GPS group experienced a longer median survival in the reported analysis.

However, median survival does not describe every patient's experience. Some participants may have lived substantially longer than the median, while others may have died earlier. It is a summary measure for the group, not an individual prediction.

The result should also be considered alongside the hazard ratio, confidence interval, survival curves, patient characteristics, follow-up duration and other prespecified analyses. Those details are necessary to understand the robustness and clinical interpretation of the findings.

Sellas' November 17 announcement provides the topline median survival, hazard ratio and p-value. The company said comprehensive statistical evaluation of secondary endpoints and additional prespecified analyses was still underway, with detailed results expected to be presented at a future major medical meeting and submitted for peer-reviewed publication.

Until those materials are available, reporting should remain anchored to the figures disclosed by the company rather than assuming that every aspect of the trial has been fully evaluated publicly.

  1. What the hazard ratio of 0.59 means

The reported hazard ratio was 0.59. In this comparison, that corresponds to a 41% relative reduction in the hazard of death for participants assigned to GPS compared with those assigned to best available treatment.

The calculation is straightforward: one minus 0.59 equals 0.41, or 41%.

A hazard ratio compares the relative rate at which an event occurs over the analysed follow-up period. It is not the same as an absolute reduction in the percentage of patients who die, nor does it mean that every patient receiving GPS has a 41% lower personal probability of death.

The distinction matters because relative risk figures can be misunderstood when presented without context. A 41% relative reduction in the hazard of death is not a 41-percentage-point improvement in survival and does not mean that 41 additional patients out of every 100 will survive.

The median overall survival figures provide a separate perspective on the observed outcomes. The hazard ratio summarises the relative event experience over time, while the median identifies the point at which half of the group has experienced the event.

The reported two-sided p-value of 0.035 indicates that the primary endpoint met the conventional 0.05 statistical significance threshold under the trial's analysis. Statistical significance does not by itself establish the size of the benefit for every patient or resolve all questions about clinical relevance, safety and durability.

  1. The role of the 80-death event trigger

REGAL was an event-driven study. Rather than conducting its final primary analysis on a fixed calendar date, the trial's final analysis was linked to the occurrence of a prespecified number of deaths.

Sellas announced on October 28, 2026, that the 80th death event had occurred. This triggered the final analysis according to the trial's statistical plan.

The event-driven design is common in survival studies because the number of outcome events can be more important to statistical analysis than the passage of a particular number of months. A trial may need to continue follow-up until enough events have occurred to support the planned comparison.

The company had previously reported that an interim analysis was conducted after 60 deaths. In January 2025, the independent data monitoring committee recommended that the study continue without modifications.

The final analysis after 80 events was therefore a planned stage of the study, not an unscheduled response to a sudden change in the results.

The November 17 announcement reported the outcome of that analysis. Sellas said further secondary-endpoint and prespecified evaluations would follow.

  1. What is galinpepimut-S?

Galinpepimut-S, also known as GPS, is an investigational off-the-shelf immunotherapeutic cancer vaccine designed to target the Wilms Tumor 1 protein, commonly abbreviated as WT1.

WT1 is a protein expressed in several malignancies, including AML. The GPS approach is designed to direct the immune system toward cancer cells expressing this target.

Unlike a conventional preventive vaccine designed to protect against an infectious disease, GPS is a therapeutic cancer vaccine. Its purpose is to stimulate an immune response against cells associated with an existing malignancy.

Sellas describes GPS as a multivalent peptide vaccine containing four WT1-derived peptides. The formulation is designed to generate immune responses across multiple human leukocyte antigen (HLA) types, which are involved in presenting antigen fragments to immune cells.

The company says the vaccine is designed to stimulate both CD4-positive and CD8-positive T-cell responses. These immune-cell populations perform different but complementary roles in recognising and responding to abnormal cells.

The programme was licensed from Memorial Sloan Kettering Cancer Center and was discovered in the laboratory of David A. Scheinberg.

  1. How the WT1-targeting approach is intended to work

The scientific rationale behind GPS centres on the immune system's ability to recognise proteins associated with cancer cells.

A peptide vaccine contains short protein fragments that can be presented to the immune system. In the case of GPS, the peptides are derived from WT1 and are intended to stimulate immune recognition of WT1-expressing malignant cells.

CD8-positive T cells can recognise antigen fragments presented through specific HLA class I molecules and may directly attack target cells. CD4-positive T cells can support and coordinate immune responses, including by helping other immune-cell populations develop effective activity.

The four-peptide design is intended to broaden immune recognition across multiple HLA types. This is relevant because HLA characteristics vary among individuals and can influence how peptide fragments are presented to the immune system.

The therapeutic objective is to encourage immune surveillance against residual leukemia cells that may remain after salvage treatment has produced remission.

That mechanism is biologically plausible and forms the basis of the development programme. However, the clinical result must be distinguished from the mechanism proposed by the developer. The trial's survival outcome is the clinical evidence; it does not, on its own, establish every detail of how the immune response contributed to that outcome in individual participants.

Further immune-response, biomarker and subgroup analyses may help researchers understand the relationship between WT1 targeting and the observed survival difference.

  1. Why a maintenance vaccine could matter after remission

AML treatment often involves multiple stages. Initial therapy attempts to induce remission, while subsequent treatment may be used to reduce the risk of relapse or consolidate the response.

For patients who cannot undergo transplantation after achieving a later remission, maintenance treatment is an important area of investigation.

A maintenance strategy aims to control residual disease over time rather than treating only visible or rapidly progressing cancer. In theory, an immune-based approach could provide a way to target residual malignant cells through ongoing immune recognition.

GPS is being developed for this purpose. It is administered as an investigational maintenance monotherapy in the REGAL population.

The appeal of an off-the-shelf peptide vaccine is also relevant to development and manufacturing. A product that does not require an individually manufactured treatment for every patient could potentially be easier to distribute than highly personalised cellular therapies. Nevertheless, practical availability, dosing, manufacturing consistency, storage, administration and reimbursement would still need to be addressed if the product eventually receives approval.

A positive Phase III result is a significant step, but it does not establish that GPS is ready to replace existing maintenance strategies or that it will become the standard of care. Those questions require full data review, regulatory assessment and consideration by the clinical community.

  1. Safety findings: encouraging topline disclosure, not the complete assessment

Sellas reported that GPS was generally well tolerated in REGAL. The company said its safety profile was consistent with prior clinical experience and that no new safety signals had been identified.

Treatment-related adverse events were reported as predominantly mild to moderate, generally Grade 1 or Grade 2. The most common events described in the announcement were local injection-site reactions.

This is encouraging in the context of a maintenance therapy, where patients may receive treatment after having already undergone intensive salvage therapy. Tolerability can be important when clinicians assess whether a treatment is suitable for continued use.

However, a topline safety statement is not a substitute for the complete safety dataset. The full frequency and severity of adverse events, serious adverse events, discontinuations, treatment exposure and any differences between study arms will need to be assessed when detailed results are released.

Sellas also stated that the treatment groups were balanced for prognostic stratification factors and that the number of patients who proceeded to hematopoietic stem-cell transplantation was limited and equally distributed between the arms.

Those details are relevant because subsequent transplantation and other post-study interventions can influence survival analyses. The full dataset will be needed to understand the impact of these factors.

  1. What the result means for Sellas Life Sciences

For Sellas, the REGAL announcement is a major clinical development milestone. The company has reported that its lead investigational asset met the primary endpoint of a pivotal Phase III study.

A positive overall-survival result can strengthen a biotechnology company's position in regulatory discussions, partnership negotiations and future development planning. It may also change how investors assess the potential value of the programme.

But a successful topline announcement does not remove the remaining development and regulatory risks.

The company still needs to provide detailed clinical information, discuss the results with the FDA, determine the appropriate filing pathway and prepare the required regulatory documentation. The regulator will evaluate the totality of the evidence, including efficacy, safety, manufacturing quality and the proposed product labelling.

Sellas has said it intends to meet with the FDA to discuss an accelerated filing strategy and is preparing for a possible BLA submission in the first half of 2027.

That is a company plan. It is not evidence that the FDA has agreed to accelerated approval, endorsed a filing strategy or accepted a BLA for review.

  1. The regulatory pathway: from Phase III result to potential BLA

A Biologics License Application is a formal request to the FDA for permission to market a biological product in the United States.

A BLA submission generally includes detailed information about the product's safety and effectiveness, manufacturing processes, quality controls, proposed labelling and other regulatory requirements.

For GPS, the first step announced by Sellas is a planned discussion with the FDA about the regulatory path forward. The company has indicated that it intends to explore an accelerated filing strategy and prepare for a possible submission during the first half of 2027.

The term accelerated filing should not be confused with an already granted accelerated approval. The FDA would need to assess the evidence and determine whether the programme meets the applicable requirements for the proposed regulatory route.

The company will also need to provide the comprehensive analysis of the trial. That includes secondary endpoints and additional prespecified evaluations that Sellas says are currently being assessed.

A future submission would be reviewed on the basis of the full evidence package. The FDA may request additional information or determine that further clinical or manufacturing evidence is needed.

For this reason, the REGAL result should be viewed as a pivotal development milestone rather than the completion of the regulatory process.

  1. Why the full dataset still matters

Topline results provide the principal outcome announced by a company, but they do not always contain the information needed for a complete scientific assessment.

For REGAL, several details will be important when the full results become available.

These include the confidence interval around the hazard ratio, the shape of the overall-survival curves, the number and timing of events in each group, the duration of follow-up and the results of secondary endpoints.

Researchers will also examine whether the treatment effect was consistent across prespecified patient subgroups and whether baseline characteristics were balanced.


Corrections and updates

Nexuswild welcomes factual corrections. Email contact@nexuswild.com with evidence and the article URL.